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Background: Skin-to-skin contact (SSC) between mother and infant, commonly referred to as Kangaroo Mother
Care (KMC), is recommended as an intervention for procedural pain. Evidence demonstrates its consistent efficacy
in reducing pain for a single painful procedure. The purpose of this study is to examine the sustained efficacy of
KMC, provided during all routine painful procedures for the duration of Neonatal Intensive Care Unit (NICU)
hospitalization, in diminishing behavioral pain response in preterm neonates. The efficacy of KMC alone will be
compared to standard care of 24% oral sucrose, as well as the combination of KMC and 24% oral sucrose.
Methods/design: Infants admitted to the NICU who are less than 36 6/7 weeks gestational age (according to early
ultrasound), that are stable enough to be held in KMC, will be considered eligible (N = 258). Using a single-blinded
randomized parallel group design, participants will be assigned to one of three possible interventions: 1) KMC, 2)
combined KMC and sucrose, and 3) sucrose alone, when they undergo any routine painful procedure (heel lance,
venipuncture, intravenous, oro/nasogastric insertion). The primary outcome is infant’s pain intensity, which will be
assessed using the Premature Infant Pain Profile (PIPP). The secondary outcome will be maturity of neurobehavioral
functioning, as measured by the Neurobehavioral Assessment of the Preterm Infant (NAPI). Gestational age, cumulative
exposure to KMC provided during non-pain contexts, and maternal cortisol levels will be considered in the analysis.
Clinical feasibility will be accounted for from nurse and maternal questionnaires.
Discussion: This will be the first study to examine the repeated use of KMC for managing procedural pain in preterm
neonates. It is also the first to compare KMC to sucrose, or the interventions in combination, across time. Based on the
theoretical framework of the brain opioid theory of attachment, it is expected that KMC will be a preferred standard of
care. However, current pain management guidelines are based on minimal data on repeated use of either intervention.
Therefore, regardless of the outcomes of this study, results will have important implications for guidelines and practices
related to management of procedural pain in preterm infants.
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Even in the context of critical care, mothers can provide
comfort to their preterm neonates during painful proce-
dures. Skin-to-skin contact (SSC), commonly referred to
as Kangaroo Mother Care (KMC), is recommended as an
intervention for procedural pain in guidelines by the
Canadian Pediatric Society and the American Academy
of Pediatrics [1]. There are now more than 18 studies
showing consistent efficacy of KMC in reducing pain
from a single painful procedure [2,3]. These same guide-
lines also recommend 24% oral sucrose for common
procedural pain based on more than 57 studies [4]. Des-
pite some concerns with the influence of sucrose on
neurodevelopmental outcomes [5,6], sucrose is consid-
ered standard care for management of procedural pain
in most Neonatal Intensive Care Units (NICUs) [7].
It is assumed that KMC, shown to be effective for
managing pain in neonates during single events, will re-
main efficacious over time. However, as no studies have
examined its repeated use, this is unknown. In addition,
as the mechanism underlying oral sucrose and KMC
are thought to differ (sweet taste is believed to release
endorphins and KMC believed to release oxytocin), the
interventions could have synergistic effects when used
in combination. The purpose of this study is to examine
the sustained efficacy of KMC in diminishing pain re-
sponse in preterm neonates compared to standard care
of oral sucrose, as well as examine the combination of
KMC and oral sucrose. Infant’s neurodevelopment at term
equivalence will also be compared between groups.
Summary of literature review
Pain in the NICU
More than two decades ago, two Canadian surveys exam-
ining pain and its management in the NICU reported
under-treatment of procedural pain [8,9]. These surveys
indicated that unlike post-operative pain, which is typic-
ally treated with analgesic intervention, management
of procedural pain using analgesia was uncommon. In
these surveys, the number of tissue damaging procedures
was documented as averaging from 2 to 8 per infant [8].
The findings of these Canadian surveys are consistent
with the findings of surveys conducted in the US [10,11]
and UK [12].
More recently, surveys conducted in Canadian, Dutch,
and French NICUs indicate that infants undergo a similar
number of procedures with almost 50% of all tissue break-
ing procedures associated with little or no analgesia
[13-15]. The under management of pain noted within
the literature has been reported in spite of guidelines
recommending analgesia and comfort measures in neo-
nates undergoing medical procedures [1], as well as the
fact that most neonatal staff believe that infants are cap-
able of experiencing pain from a very early age [13].Treatment of procedural pain
Pharmacologic agents
Pharmacologic agents that have been examined for redu-
cing procedural pain in neonates include topical anesthetics
and systemic drugs, such as opioids or acetaminophen.
Topical anesthetics, while effective for pain management
during circumcision [16-20], have been shown to be
ineffective for heel lance, venipuncture, and insertion
of intravenous lines [21-25]. Systemic drugs, specifically
opiates, are highly sensitive to the developmental stage
of the infant [26,27]. Therefore, rapid changes in require-
ments make effective and safe dosing a challenge. In
addition, opiates have significantly slower clearance in
neonates [28-32], and have not necessarily been demon-
strated as effective for managing procedural pain [33].
Trials of acetaminophen for procedural pain control have
demonstrated that it is not effective, and may even be
no better than placebo for heel lance procedure [34,35].
Thus, pharmacological management for common, repeated,
painful procedures in preterm neonates is not an option.
Given the frequency of painful procedures in NICUs, the
short and long term negative effects of repeated pain expos-
ure in this population, and the ethical imperative to manage
this pain, other approaches are required.
Alternative methods of procedural pain control
Non-pharmacological approaches to pain management are
thought to be based on the release of endogenous opiates
[36,37]. Although there are scant data in neonates re-
garding endogenous descending inhibitory mechanisms,
the engagement of mechanisms that release endorphins
is well established in adults [36,37]. Animal studies sug-
gest that the endogenous system is not well developed
prior to 32-weeks post-conception, however, there is specu-
lation that it may be developed enough to provide some
level of comfort [38,39]. Various non-pharmacological strat-
egies for pain control have been tested in neonates and
show varying degree of efficacy. These strategies can
be categorized into sensory stimulation [40,41] (i.e.,
positioning/swaddling, vestibular action/rocking, non-
nutritive sucking, music), nutritive [42-63] (i.e., breast-
feeding, oral sweet solutions), and maternal interventions
(i.e., maternal odor and voice, breastfeeding, KMC). For
the purposes of this trial, KMC and 24% oral sucrose
(considered standard care) are the interventions of interest.
Sucrose
Research in animals and human infants have shown that
intra-oral sucrose solutions have an analgesic effect. Stud-
ies using sucrose for pain relief started in the late 1980’s
[50-52] and have since included both term and preterm
infants. Sucrose, the oral solution used most frequently,
has been examined in two systematic reviews [50,62], and
one meta-analysis [4]. These reviews are in agreement
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procedural pain in preterm neonates.
Infant response to interventions has been assessed using
both behavioral (e.g., cry and facial action) and physio-
logical indicators, as well as composite measures of pain.
A recent study demonstrated that although sucrose de-
creased scores on the Premature Infant Pain Profile
(PIPP), there was still nociceptive activity in the somato-
sensory cortex [63]. Given the dissociation between the
affective components of pain [64-66], that is how much
it hurts (somatosensory cortex) vs. how aversive it is
(frontal and pre-frontal cortex), it is likely that it is the
affective component of the pain response that is being
modified by sucrose. The authors of the study thus raised
concerns about the analgesic properties of sucrose, and
whether it can ameliorate the adverse effects of repeated
pain exposure. Such findings reinforce the need for con-
tinued study of other non-pharmacological interventions
such as KMC alone or in conjunction with sucrose.
The effect of sucrose on pain intensity on consecutive
days has been addressed, but needs further investigation.
While one study examining the use of sucrose for all
painful procedures in the first week of life in the NICU
reported poorer neurodevelopmental outcome scores with
higher doses of sucrose [6], a secondary analysis found
that this was only the case in infants who received more
than 10 doses over 24 hours [67]. Concerns about the
long-term use of sucrose on neurodevelopmental out-
comes have also been raised by Holsti and Grunau [5].
They provide a strong and logical argument that the de-
velopment of the infant’s dopaminergic system is altered
with sucrose administration. Specifically, that sugar stimu-
lates dopamine release, and that this release responds or
is a reaction to the concentration of sucrose rather than
the volume. In addition to this argument, there is also a
relationship between dopamine and attention and motor
development – the specific neurodevelopmental outcomes
used in the study examining repeated sucrose adminis-
tration [6]. Holsti and Grunau suggest that dopamine
regulation is disturbed by receiving repeated doses of
24% sucrose (the recommended concentration for pro-
cedural pain management in neonates), and that this
interferes with attention and motor development.
Kangaroo Mother Care
Kangaroo Mother Care (KMC) was implemented in the
modern era as an alternative to incubator care to main-
tain preterm infants’ body temperature and increase survival
rates in South America due to short supply of incubators
[68]. During this time, it was serendipitously noted that
infants in KMC spent more time in quiet sleep state
[69,70]. As quiet sleep state is associated with decreased
pain response [71,72], the idea developed to use KMC
to control procedural pain. When initially studied in fullterm neonates, decreased crying and heart rate acceler-
ation was observed [73]. Subsequent studies in preterm
neonates showed decrease in facial action, decrease in
heart rate acceleration, and increased oxygen saturation,
with a decrease in overall pain scores [74].
In a recent Cochrane review of the literature on skin-
to-skin contact for procedural pain in infants conducted
by the authors of this protocol [3], 13 studies that met
the inclusion criteria showed positive results. Interestingly,
two of the studies [75,76] showed that KMC was more
efficacious than sweet taste in reducing infant’s proced-
ural pain. However, to our knowledge, there have been
no published studies to date examining the combined
efficacy of KMC and sucrose in managing procedural
pain in preterm infants.
Mechanism underlying KMC as a comfort strategy
There are likely several mechanisms underlying the spe-
cific pain-relieving effect of KMC. One hypothesis that
could be related to all non-pharmacological strategies is
derived from the Gate Control Theory of Melzack and
Wall [36]. According to this theory, stimuli travelling as-
cending pathways may inhibit the nociceptive signals from
painful stimulus through various endogenous mechanisms
located along the spino-thalamic tract [77]. The stronger
these competing stimuli are, including multiple modal-
ities, the more effective they are at blocking the percep-
tion of pain. Such theories help explain why multiple
modalities, such as KMC, breastfeeding, or sensorial sat-
uration that involves tactile, auditory, and olfactory mech-
anisms are more effective than single modalities.
The mechanism of the comforting effect of breastfeed-
ing and KMC is likely related to the release of oxytocin
[78,79]. Oxytocin has been referred to as the love hor-
mone due to its role in affiliative behaviors [80-83]. In an
animal model of pain and oxytocin, massage-like stroking
induced acute antinociception that was reversed by an
oxytocin antagonist [84]. Also, when oxytocin was injected
into the periaqeductal gray region, it had an antinoci-
ceptive effect.
In summary, 1) procedural pain in the NICU is infre-
quently and poorly managed, 2) pharmacological interven-
tions present problems with this population, 3) among
non-pharmacological interventions both sucrose and KMC
are supported by numerous studies as one-time interven-
tions in diminishing pain response, 4) there are no studies
of repeated use of KMC and only two studies that have
followed infants for repeated use of sucrose over time
have had conclusive results, 5) no published studies to
date have examined the combination of KMC and sucrose
across time.
Given the findings of research to date, this study pro-
poses that KMC alone or in combination with sucrose
will continue to reduce pain across the NICU stay more
Figure 1 TRAKC Trial CONSORT Flow Diagram.
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touch and olfactory senses invoked from the mother are
fundamental to the maternal role of affiliation and com-
fort through underlying mechanisms of hormone release.
It is further proposed that neurodevelopment will be
better in infants who have received KMC for minor
painful procedures due to the release of norepinephrine
during KMC.
Theoretical framework
Nelson and Panksept’s Brain Opioid Theory of Social At-
tachment provides the conceptual framework for this study
[79]. This theory, based on animal experimentation, pos-
tulates that maternal touch, smell, (and milk) release en-
dogenous opiates, which are known to reduce pain and
promote affiliative behaviors. There are other hormones
involves in mother-infant attachment and comforting,
namely oxytocin and epinephrine. Oxytocin, as described
above, is the primary hormone promoting affiliation, is
released with social contact, and also appears to have
antinociceptive effects [84].
Hypotheses
The hypotheses of this study are as follows:
i. Pain response to heel lance or venipuncture for
blood sampling, as measured by the Premature
Infant Pain Profile (PIPP), will be lower by 1.5 points
in KMC alone than sucrose alone. The combination
will be marginally better (0.5 on PIPP scale) for a
total of 2 points between combination and sucrose
alone and 0.5 points between KMC alone and
combination.
ii. This difference in PIPP scores will remain across the
infant’s hospitalization.
iii. Neurodevelopmental sub-scores of the Neurobehavioral
Assessment of the Preterm Infant (NAPI) of 1)
motor development and vigor and 2) alertness and
orientation at discharge from the NICU will be
significantly higher in infants in the KMC groups
than the sucrose alone group.
A no-treatment control group will not be used in this
study, as it is believed to be unethical given that it has
been argued that a state of equipoise has been reached
with sucrose [85], and it is considered the standard of
care. According to the hypotheses listed above, it is pro-
posed that KMC will be a preferred standard of care.
Methods
Trial design
TRAKC is a single-blinded, randomized, parallel group
design (Figure 1). The coders assessing the data will be
blind to group assignment; however, the person completingthe blood sampling will not be blind as it is impossible
to prevent them from knowing participant KMC condi-
tion (i.e., skin-to-skin or incubator care).
Participants
The sample will consist of 258 infants born less than
36 6/7 weeks gestational age according to the early
ultrasound, that are stable enough to be held in KMC,
whose mothers consent and expect to be available for
KMC. Determination of infant physiological stability
will be confirmed by the attending neonatal staff. Infant
exclusion criteria are major congenital anomalies, receiv-
ing narcotics, or surgery. Infants will be enrolled within
5 days of birth.
Sample size
The primary analyses of this study will be hierarchical
linear modeling (growth curve analysis). Given that there
are no acceptable methods for calculating sample size for
this design, sample size estimates are based on Repeated
Measures Analysis of Variance (RM-ANOVA). As a slope
is being proposed in this study, with between group dif-
ferences being specified, then across the slope (time),
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and thus the sample size should be the same at any
point in time. In studies using RM-ANOVA, the sample
size is based on group differences, and a similar principle
applies. Given this, a sample of 258 will provide a power
of 0.9 to detect a difference of 1.5 points (considered to be
a clinically significant difference) with a standard deviation
of 3 on the PIPP.
Study setting
The study setting is the NICU of a tertiary-level Canadian
hospital specializing in women and children’s health.
Enrollment began in July of 2012, and is expected to be
completed within 42 months of initiation.
Randomization
Sequence generation
Group assignment will be determined using a password
protected website, where randomization is in permuted
blocks and participants will be stratified by gestational
age (less than or greater than/equal to 32 weeks gesta-
tional age at birth) in order to ensure equal distribution
across groups for all ages.
Implementation
Group assignment will be acquired by the research nurse
from the secure website. The REB approved research
nurse is the only individual in this study who has access
to the secure site after consent is obtained.
Allocation concealment mechanism
The pharmacy at the study site will supply the syringes
containing the study solution. Of the study syringes, 1/3
will contain sterile water and 2/3 will contain 24% sucrose.
The study solutions will be labeled with a code known
only by pharmacy and the research nurse. Solutions will
be prepared and packaged in an identical matter. Upon
knowing infant group assignment, the research nurse
will label each syringe with the infants study number
and name to ensure added protection. Each participant
will be provided syringes at his/her bedside and the
research nurse will conduct regular syringe counts to
evaluate compliance.
Procedures
Documented approval has been obtained from the REB
of the study site. When an eligible infant becomes
available, the research nurse will explain the study to
the parents, answer questions, determine the mother’s
availability to provide KMC, and obtain written informed
consent.
A minimum of 3 painful procedure sessions will be
video-recorded with each infant, with each session being
a minimum of 24-hours apart. For infants less than orequal to 32 weeks, sessions will be recorded as close to
recruitment as possible, at 32 weeks, 36 weeks, and
prior to discharge. For older infants, the sessions will be
spaced as evenly apart as can be estimated. The research
nurse will coordinate the timing of the procedure-
recording with the staff, call parents to tell them that
the procedure is taking place at a given time, and tell them
the KMC condition (i.e., skin-to-skin or standard care).
The research nurse will mark phases on the recordings
by holding colored cards briefly in front of the video cam-
era. These phases will include baseline 1 at beginning
of monitoring, baseline 2 prior to procedure initiation,
heel warming or vein site cleansing, painful procedure
(i.e., heel lance or venipuncture), application of bandage,
and heart rate return to baseline. The research nurse
will ensure that monitoring remains intact, and that the
camera is focused on the infants face at an angle that
makes the infant appear prone in an incubator in order
to keep coders naïve [74]. Phases will be matched to the
built in timer of the Somte monitor used to record
physiologic data.
Depending on the gestational age of the infant, neuro-
developmental assessments using the Neurodevelopmen-
tal Assessment of the Preterm Infant will be conducted at
32 weeks, 36 weeks, and/or term equivalence by a trained
research assistant who will be kept blind to group
assignment.
Mothers will be asked to keep a diary about the amount
of time they provide KMC regardless of group assignment.
As one study has demonstrated that mothers stress in the
NICU decreases with KMC [86], and as there is a plaus-
ible relationship between maternal cortisol levels and in-
fant reactivity [87], there is an interest in studying maternal
stress levels over time. Therefore, salivary cortisol samples
will be collected from the mothers shortly after enrollment
of the infant, halfway through the stay, and near NICU dis-
charge. Samples will be collected near morning awakening
in order to obtain basal cortisol levels, which are more re-
flective of trait anxiety as opposed to state anxiety. This
data is exploratory, and will be correlated over time with
infant pain response, accounting for group assignment.
Mothers will also be asked 2–4 questions (depending on
randomization) regarding their experience with provid-
ing KMC to their infants during hospitalization.
In addition to having mothers answer questions regard-
ing KMC, nursing staff will also be questioned. At the
beginning of the study, nurses will be asked to answer
informal investigator questions aimed at assessing their
attitudes toward KMC as an intervention for painful proce-
dures. The questionnaires will be repeated every 6 months
throughout the study. It is anticipated that nurses will
have progressively more positive attitude toward KMC
as an intervention as the study progresses. While attempts
will not be made to sample the same nurses over time, the
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If the infant is randomized to the KMC condition, the re-
search nurse will begin by recording a one-minute sample
of the infant in the incubator. The research nurse will then
place the mother and infant into the KMC condition,
where the diaper-clad infant is help upright, at an angle
of approximately 60°, between the mothers breasts, provid-
ing maximal skin-to-skin contact between mother and
baby. The infant will remain in KMC for at least 15 minutes
prior to the painful procedure. Two minutes prior to the
procedure the infant will receive ¼ of the recommended
(based on NICU protocol) volume of sterile water by
syringe onto the tongue. The remainder of the total rec-
ommended dose will be given as needed in small incre-
ments during the procedure.
Sucrose condition
If the assigned condition is sucrose alone, half an hour be-
fore the procedure the nurse will place the infant in the
supine position in an incubator or infant cot and set up
the monitoring equipment. All monitoring will take place
while the infant is in the incubator or cot. Two minutes
prior to the procedure, the baby will receive ¼ of the rec-
ommended volume (based on NICU protocol) of 24% oral
sucrose solution by syringe onto the tongue. The remain-
der of the total recommended dose may be given as
needed in small increments during the procedure.
Combined KMC and sucrose condition
For combined sucrose and KMC, the infant will be placed
in KMC as described for the KMC alone condition, how-
ever, will receive 24% oral sucrose solution as per the
NICU protocol described above.
Although most painful procedures will not be video-
recorded for the study analysis, the expectation is that
the staff caring for infants enrolled in the study will fol-
low the study intervention protocol for all painful proce-
dures, and that any deviations from the study protocol
will be charted and included in the analyses. Babies in
the KMC group will have reminder signs at the bedside
prompting the staff to place them in KMC for procedures,
and the study syringes of either 24% sucrose solution or
sterile water will be available to staff at the bedside
throughout the infant’s stay in the NICU. Staff docu-
mentation of all painful procedures will be monitored to
ensure compliance with the study protocol.
In order to ensure equipoise, staff may deviate from
the protocol to give off-study doses of rescue sucrose ifthe infant has a PIPP score > 6 (considered to indicate
pain) at their discretion. The deviations from protocol will
be recorded on a procedure record kept at each infant’s
bedside. If the mother is unavailable for a painful pro-
cedure, the infant will be swaddled and given the study
solution. If the infant has a PIPP score > 6, off-study
sucrose may be given by the nurse caring for the patient.
All off-study sucrose doses will be recorded in the proced-
ure record and the research nurse will confirm the doses
given from the medication administration record.
Outcomes
Premature Infant Pain Profile (PIPP)
The primary outcome in this trial will be infant pain
intensity measured by the Premature Infant Pain Profile
(PIPP) [72,88]. The PIPP uses seven indicators to calculate
a composite pain measure: three behavioral indicators
(facial actions of brow bulge, eye squeeze, and nasola-
bial furrow), 2 physiological indicators (heart rate and
oxygen saturation), and 2 contextual indicators (gesta-
tional age and behavioral state) [72]. The contextual fac-
tors included in the PIPP are particularly important for
this study as infants are being followed over time and
therefore age changes will be accounted for. In addition,
KMC is known to promote quiet sleep state, and this
will be accounted for when considering behavioral state
as an indicator in the PIPP scoring. The PIPP was devel-
oped 13 years ago and has steadily accumulated evidence
of reliability and validity [72,88]. It had been used in over
40 studies to date [88].
This study will utilize a Somte (Compumedics,
Melbourne, Australia) system that samples at a rate of
256 Hz to measure physiological data. Heart rate and
oxygen saturation are recorded to the Somte system
using a transcutaneous probe, and Electrocardiogram (ECG)
is recorded from 3 leads. Epochs will be noted with an
event timer in the Somte system. Close up video record-
ings of the infants face will be made using a Sony DCR-
SR82 HDD digital video camera in the first baseline in
the incubator (Baseline 1), one minute prior to start of
procedure (Baseline 2), and during and after the proced-
ure. The neurobehavioral state component of the PIPP
score is determined according to Prechtl’s categories of
quiet sleep, quiet awake, active sleep, or active awake
[89], during the baseline [90]. Gestational age will be
taken from the infant chart, and will be based on ultra-
sound at 16 weeks.
All data will be analyzed in the research laboratory out-
side the NICU. Physiologic data will be analyzed using
Compumedics E-series Profusion PSG II software. Faces
will be coded second-to-second on a stop frame system by
trained coders naïve to the purpose of the study. Coders
will be trained up to 90% agreement on video recordings
from previous studies. Every three months, coders will
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coding and one from each of the other coders) in order to
determine both inter and intra-rater reliability.
Neurobehavioral Assessment of the Preterm Infant (NAPI)
The secondary outcome will be the Neurobehavioral
Assessment of the Preterm Infant (NAPI), developed by
Korner and colleagues [91-95]. In particular, the sub-
scales of alertness and orientation and motor develop-
ment and vigor will be assessed. The NAPI evaluates the
relative maturity of functioning of preterm infants, with
higher scores reflecting higher maturity, and can differ-
entiate 2 weeks’ post-conceptual age. Assessments at 32
and 36 weeks corrected gestational age and at term
equivalence will be preformed on all infants in accord-
ance with their gestational age at birth, as well as at the
time of discharge from the NICU. Much of the NAPI
examination consists of observational items, and the
remainder rates the infant’s response to stimuli. The
assessment takes approximately 30 minutes to admin-
ister and includes clusters of single-item neurobehavioral
dimensions. Test – re-test reliability ranging over 2 con-
secutive days ranged from 0.59 to 0.90. Original inter-
observer reliability ranged from 0.64 to 0.93 [91].
Clinical and construct validity and sensitivity of the
NAPI have been established [94,96].
Other outcomes
Severity of medical risk at birth will be assessed by the
SNAP-II (Simplified Newborn Illness Severity and Mor-
tality Risk Score). Daily number tissue-damaging proce-
dures will be recorded from the chart and the number
of hours spent in KMC will be taken from a diary given
to the mother. Mothers will also provide baseline saliv-
ary cortisol samples upon awakening on the days infants
undergo a video-recorded medically required painful
procedure.
Statistical analysis
Analysis and inference will be based on the intention-to-
treat principle. Descriptive and correlational analysis will
be performed to identify potential confounding variables.
The data will be analyzed using growth curve analysis.
In this analysis, a regression line is fitted to each infant’s
responses over time, and a slope and intercept is derived
for each curve. The data will be centered so that the last
time period is coded as 0, allowing for the comparison
of the three groups, as well as the differences at final as-
sessment. The advantage of this analysis is that 1) data
can be missing as long as there are three data points,
and 2) the spacing of the interventions does not have to
be the same for all participants. This analysis will there-
fore answer all research questions: 1) what is the trend
across time? (i.e., comparing slopes), 2) is KMC moreefficacious than sucrose at reducing pain? (i.e., comparing
the intercepts at the final assessment), and 3) is the com-
bination of KMC and sucrose more powerful than either
alone? Potential cofounders that may need accounting for
in the statistical model include number of tissue damaging
procedures, number of hours of KMC in total, number
of doses of sucrose in total, SNAP-II score at birth, and
gestational age at birth in days.Ethical considerations
Authorization and informed consent will be obtained from
the mother of each eligible infant prior to study entry, and
a copy of the consent form will be provided to participants
once signed. Participation in the study is voluntary, and
mothers will be made aware of their rights to withdraw
their infants’ participation at any time throughout the
course of the study. This study provides no direct bene-
fit for the mothers or infants enrolled and compensation
for study participation will not be offered.
Provision of KMC during painful procedures is not con-
sidered to be a standard of care in the NICU at the study
site. While KMC is considered a safe practice for stable in-
fants, all participants will be closely monitored with regard
to any adverse events associated with being transferred
into KMC. Administration of sucrose is considered stand-
ard care in the NICU at the study site. In order to ensure
equipoise, NICU staff will be permitted to give off-study
doses of sucrose if the infant has a PIPP score greater
than 6, which is indicative of pain. Infants will be moni-
tored as per NICU standard of care, and their clinical con-
dition will be evaluated daily as part of medical rounds.
All procedures that infants undergo will be part of their
routine NICU care and will not be conducted solely for
the purpose of this study.Discussion
This will be the first study to examine the repeated use
of KMC for reducing pain response in preterm neonates.
It is also the first to compare sucrose to KMC, or the
interventions in combination, across time. Based on the
theoretical framework of the brain opioid theory of attach-
ment, it is fully expected that the results will be as hypoth-
esized. However, current pain management guidelines are
based on minimal data on repeated use of either interven-
tion. Therefore, regardless of the outcomes of this study,
results will have important implications for guidelines
and practices related to management of procedural pain
in preterm infants.
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